Since its introduction by Morton in 1992 ([Morton *et al*, 1992](#bib17){ref-type="other"}) sentinel lymph node biopsy (SLNB) has become a standard procedure in the staging and treatment of primary melanoma ⩾1 mm tumour thickness and clinically negative regional lymph nodes. According to Morton, the sentinel lymph node (SLN) can be defined as 'the lymph node nearest the site of the primary melanoma, on the direct drainage pathway\'.

Primary aims of this procedure were (i) to ascertain individual lymphatic drainage patterns of the primary tumour towards one or more different lymph node basins and (ii) to detect patients with micrometastatic lymphatic disease for selective lymphadenectomy (SL), which has been beneficial at least in subsets of melanoma patients ([Balch *et al*, 1996](#bib2){ref-type="other"}).

Indeed SLN status has been found to be the strongest prognostic factor for survival and recurrence in patients with melanoma and clinically negative lymph nodes in a multicentre trial with 612 patients ([Gershenwald *et al*, 1999](#bib11){ref-type="other"}). This observation was also taken into account at the revision of the staging system for cutaneous melanoma under the auspices of the American Joint Committee on Cancer (AJCC) in 2001. They concluded that 'the information obtained from examining the sentinel node has an important impact on the staging of the disease, treatment planning, and the conduct of clinical trials in melanoma patients\' ([Balch *et al*, 2001](#bib1){ref-type="other"}).

We have performed SLNB in more than 300 patients with melanoma stage I/II, all according to the same protocol. In this cohort of patients, we evaluated the accuracy of this procedure and the effect of SLN status on disease-free and overall survival.

PATIENTS AND METHODS
====================

Between 1998 and 2003, SLNB has been performed in 309 consecutive patients. All tumours were diagnosed by primary excision with a tumour margin ⩽0.5 cm. Indications for SLNB were Breslow tumour thickness ⩾1 mm, Clark level ⩾IV, ulceration and lesions with signs of regression or subungual localisation of the primary melanoma. Before SLNB, evidence of macrometastatic disease in regional lymph nodes or distant sites was ruled out by physical examination and individual staging procedures such as ultrasound, chest X-ray and computed tomography. Patients with tumour-positive SLNs were subjected to SL. All patients with primary melanoma ⩾1.5 mm thickness were considered for low-dose IFN*α*-2b therapy and patients with additional positive lymph nodes upon SL were considered for adjuvant high-dose interferon therapy according to [Kirkwood *et al* (1996)](#bib12){ref-type="other"}. Patient characteristics are shown in [Table 1](#tbl1){ref-type="table"}. The mean age of patients was 55.8 years (range 18--86 years); 58% were male. Histolopathology showed nodular (124 patients, 40%) or superficial spreading melanoma (105 patients, 34%) in the majority of patients. Ulceration of the primary lesion was present in 65 patients (21%). The mean tumour thickness (Breslow) was 2.7 mm (range: 0.25--30 mm). Of these, five patients presented with primary lesions ranging from 4 to 10 mm and one patient with a primary melanoma of 30 mm tumour thickness. Most patients had melanoma of Clark level IV (208 patients, 67%). Breslow tumour thickness and Clark level were not taken into account in six patients because of regression (four patients) or subungual localisation (two patients) of the primary melanoma.

Lymphoscintigraphy according to Berger and Cascinelli ([Berger *et al*, 1997](#bib3){ref-type="other"}; [Cascinelli *et al*, 2000](#bib5){ref-type="other"}) was performed the day before surgery by intradermal administration of technetium-99m-labelled nanocolloid at a dose of 30--60 MBq (Nanocoll®; Sorin Biomedica, Saluggia, Italy) around the biopsy site. Dynamic and static images were obtained. Under general anaesthesia methylene blue dye (0.3--1 ml) was injected intradermally around the excisional scar. Sentinel lymph nodes were identified intraoperatively by their blue colour and/or radioactivity detected with a hand-held gamma probe (C-Trak® Surgical Guidance System, Morgan Hill, CA, USA). All blue nodes and all nodes ⩾10% of the most radioactive or 'hottest\' node were considered SLNs. Subsequently, the previous melanoma excisional biopsy scar was excised with 1 or 2 cm margin, depending on the thickness of melanoma invasion (⩽2 and \>2 mm, respectively).

Sentinel nodes were fixed in 10% neutral-buffered formalin and embedded in paraffin. Serial 4 *μ*m thick sections (average: 10 levels) were analysed by conventional histologic staining (haematoxylin and eosin (H&E)) along with immunohistochemical staining using antisera directed against the S-100 protein and the melanoma antigen HMB-45. After SL, dissected lymph nodes were analysed by H&E and immunohistochemistry by nonserial sectioning.

Follow-up was performed every 3 months by physical examination. Ultrasound of lymph node basins and abdomen as well as chest X-ray were performed every 6 months. Computed tomography, magnetic resonance imaging and FDG-PET (fluorine-18-2-fluoro-2-deoxy-[D]{.smallcaps}-glucose positron emission tomography) were performed in patients with unclear results suggestive of metastatic disease.

Continuous data were compared with the *T*-test or with the Mann--Withney test, as appropriate. The *χ*^2^ test or Fisher\'s exact test were used for the comparison of proportions. Survival analyses were performed according to the life tables method and according to the method described by Kaplan and Meier. Comparison of the survival between groups was performed with the log-rank test. A Cox proportional-hazard analysis was used for univariate and multivariate analysis to explore the effect of variables on survival. The SPSS 10.0 software package (SPSS Inc., Chicago, IL, USA) was used for all statistical analyses. All given *P*-values are two-tailed and a *P*-value of \<0.05 was regarded to indicate statistical significance.

RESULTS
=======

Sentinel lymph nodes were found in 299 of 309 patients (success rate: (100--10/3.09)=96.8%). In 10 patients, no sentinel node could be identified by either lymphoscintigraphy or blue dye. None of these patients was subjected to immediate lymph node dissection. Eight patients are still alive without any sign of continuing disease, one patient died of distant metastatic disease without evidence of lymph node metastasis and one patient was subjected to SL upon appearance of clinically positive lymph nodes after a follow-up of 20 months. Sentinel nodes were identified in one, two or three regional lymph node basins in 264 (85.4%), 30 (9.7%) and five patients (1.62%), respectively ([Table 2](#tbl2){ref-type="table"}). Among the five patients mapped in three different lymph node basins, four had primary melanoma in the lumbal region and one in the scapular region. Extra-anatomic SLNs were found in 10 of 299 patients (3.2%).

In 299 patients, a total of 640 (mean=2.1) SLNs were collected. In almost 60% of SLNB, two or more sentinel nodes were identified as either hot or blue ([Table 2](#tbl2){ref-type="table"}). Postoperative complications occurred in 7% and were mostly transient including seroma/haematoma or wound infection.

Patient characteristics stratified by SLN and SL status are shown in [Table 3](#tbl3){ref-type="table"}. Positive SLNs were identified in 69 patients (23%). Furthermore, seven patients developed recurrence in a lymph node basin that was negative by SLNB. This yields a false-negative SLNB rate of 9.2% (seven of (69+7)) and a failure rate of 2.2% (seven of 309). Ulceration, Clark level \>II and Breslow thickness were all significant variables on SLN status. Probability of finding a positive SLN increased from 4% (one of 24 patients) in patients with tumour thickness ⩽1 mm up to 50% in patients with tumour thickness of greater than 4 mm (24 of 48 patients; *P*\<0.001).

Of 69 patients with one or more positive SLN, 67 were subjected to SL (two patients refused further surgical treatment). Among the 67 patients with one or more metastatic SLN, 14 (21%) were found to bear further metastases in non-SLNs in the dissected basin upon SL. The median tumour thickness in these patients was 3.1 mm compared to 3.0 mm in patients with positive SLN only (NS, *P*=0.88) and 1.6 mm in SLN-negative patients (*P*\<0.001).

Positive SLN specimens were histologically subdivided by bearing micro- (\<2 mm in diameter) or macrometastastatic disease according to Carlson ([Carlson *et al*, 2003](#bib4){ref-type="other"}; [Table 4](#tbl4){ref-type="table"}). Micrometastasis in the SLN was found in 47 (68%) and macrometastasis in 22 (32%) of 69 patients. In the group of micrometastatic positive SLN, seven (15%) out of 47 patients presented with further metastases in the same lymph node basin after SL, compared to seven (27%) of 22 patients with macroscopically positive SLNs (NS; *P*=0.26).

Of 309 patients, 49 (15.9%) developed disease recurrence during follow-up ([Table 5](#tbl5){ref-type="table"}). The median time to progression of disease was 18 months. In the group of patients with a positive SLN, 25 (36.2%) out of 69 patients developed recurrence: 12 (17.4%) to the locoregional skin, five (7.2%) to the draining lymph node basin and eight (11.6%) to systemic sites. In patients with a negative SLN finding, 22 (9.5%) developed recurrence: six (2.6%) patients to the locoregional skin, seven (3.0%) to the draining lymph node basin and nine (3.9%) to systemic sites.

To date, 20 (6.5%) out of the 309 patients have died of metastatic disease. Of these, nine (3.9%, nine of 230) had a negative SLN, nine (13%, nine of 69) had a positive SLN and two (20%, two of 10) patients had an unknown sentinel node status. The 3-year overall and disease-free survival of the entire group of melanoma patients computed from the date of excision of the primary lesion were 90 and 75%, respectively. By univariate analysis, patients with a negative SLN had a significantly better disease-free (*P*\<0.001) and overall survival (*P*\<0.047) than patients with a positive SLN ([Figure 1](#fig1){ref-type="fig"}): The 3-year disease-free survival for negative and positive SLN patients was 82 and 55%, respectively. The 3-year overall survival for negative and positive SLN patients was 93 and 83%, respectively.

The model selected for multivariate regression was created by the forward stepwise elimination method. Analysis of several well-known prognostic factors with respect to disease-free survival are shown in [Table 6](#tbl6){ref-type="table"}: Positive SLN status (*P*\<0.001), presence of ulceration (*P*=0.026) and Breslow tumour thickness (*P*=0.02) were all statistically significant prognostic factors by multivariate analysis, whereas Breslow thickness proved to be the only statistically significant prognostic factor with respect to overall survival (*P*=0.002).

DISCUSSION
==========

Since the first reports on SLNB for stage I and II melanoma lesions appeared, there has been an overwhelming enthusiasm for this technique. Several published series have shown various kinds of methods for identification, pathological examination and selection criteria for patients who could profit most from this staging method.

In our study, one or more SLNs were identified in 299 of 309 (96.8%) patients. As we did not perform synchronous SLNB and elective lymphadenectomy, false-negative rate of SLNB can only be estimated by recurrence of metastatic disease in the draining lymph node basin. Out of 209 patients with a negative SLN finding, seven patients (3.0%) developed a nodal recurrence in the previously mapped basin upon follow-up. One additional patient presented with metastases in the groin after being mapped in the ipsilateral axillary region. This yields a false-negative sentinel rate of 9.2% and a failure rate of 2.2%, which is in accordance with previous studies ([Gershenwald *et al*, 1999](#bib11){ref-type="other"}; [Morton *et al*, 1999](#bib16){ref-type="other"}; [Morton *et al*, 2003](#bib15){ref-type="other"}; [Vuylsteke *et al*, 2003](#bib24){ref-type="other"}). As previously shown by Gershenwald, detection failure of positive SLNs most commonly occurs because conventional histologic evaluation is unable to identify occult metastatic disease ([Gershenwald *et al*, 1998](#bib10){ref-type="other"}). Furthermore, Morton reported a statistical lack in the detection of a positive SLN in patients with primary melanoma \<2.01 mm: Compared to the incidence of regional lymph node metastasis in a historical control group of patients who where treated by wide local excision only (WLE), incidence of a positive SLN is only 60%. In contrast, this procedure is shown to detect accurately metastases from thicker lesions. New methods of sentinel node labelling, reflecting the microanatomy of the lymph node by the use of carbon dye, could decrease the false-negative rate of SLNB ([Morton *et al*, 2003](#bib15){ref-type="other"}). The molecular analysis of the SLN using reverse transcription-polymerase chain reaction (RT--PCR) has been found to upstage a significant portion of SLN-negative patients. Since this method does not discriminate between melanoma metastases and nodal nevi, further investigations are needed until this procedure will become the standard of care.

Nevertheless, there is evidence that mechanisms other than failure of histopathologic examination may contribute to the failure of the SLNB technique in some patients. Li re-examined negative SLN specimens again and later of patients with regional recurrence and identified metastases in only seven of 12 false-negative SLNs in a group of 1152 patients ([Li *et al*, 2003](#bib13){ref-type="other"}).

In our study, 20% of patients with positive SLN were found to have additional lymph node metastasis upon SL. Whether elective lymph node dissection is able to improve overall survival is still a matter of debate. In a single study, early detection of occult metastatic disease in the draining lymph node basin by elective (prophylactic) lymph node dissection has been shown to increase survival when compared to therapeutic (delayed) lymph node dissection ([Cascinelli *et al*, 1998](#bib6){ref-type="other"}). On the other hand, Veronesi presented a prospective randomized clinical trial conducted by the WHO in which patients with melanoma of the limb did not benefit from prophylactic lymph node dissection ([Veronesi *et al*, 1982](#bib23){ref-type="other"}). This study was further supported by Sim, who also observed no significant difference with respect to overall survival and metastasis-free survival when patients were split into three different groups treated with WLE alone, WLE and 'immediate lymphadenectomy\', or WLE and 'delayed lymphadenectomy\' ([Sim *et al*, 1986](#bib19){ref-type="other"}). Nevertheless, 30% of patients with melanoma stage III survive more than 15 years after therapeutic lymphadenectomy ([Balch *et al*, 2001](#bib1){ref-type="other"}), but this may not be addressed by surgical removal of lymph node metastases alone.

In our study, 15.9% of all patients developed recurrence of disease. Within a median follow-up of 22 months recurrence rate for SLN-positive patients (36.2%) was significantly higher compared to SLN-negative patients (9.5%). Several studies have addressed recurrence of disease for SLN-negative and -positive patients and showed comparable results, depending on the median follow-up period ([Table 7](#tbl7){ref-type="table"}).

Pattern of recurrence for SLN-negative patients reflects previous observations ([Statius Muller *et al*, 2002](#bib20){ref-type="other"}), where relapse in the previously mapped lymph node basin is rare and equally as frequent as systemic metastasis. In contrast, systemic metastasis occurs in 11.6% of SLN-positive patients; however, the most frequent site of relapse in these patients was the locoregional skin (17.4%). Estourgie also found a substantially higher rate of local/in-transit metastases in SLN-positive patients compared to SLN-negative patients (23 and 7%, respectively). They suggested that this potentially inherent risk of the SLNB should be weighed against the possible survival benefit of early removal of nodal metastases ([Estourgie *et al*, 2003](#bib8){ref-type="other"}). A possible explanation for high local recurrence rates in SLN-positive patients in our study may be excision margins of only 1 or 2 cm for primary melanoma below or above 1.5 mm in tumour thickness, respectively. As shown by Thomas, 1-cm margin of excision for melanoma with a poor prognosis (as defined by a tumour thickness of at least 2 mm) is associated with a significantly greater risk of locoregional recurrence than is a 3-cm margin. Nevertheless, overall survival was similar in the two groups ([Thomas *et al*, 2004](#bib21){ref-type="other"}). Additionally, there might exist an inherent iatrogenic risk of SLNB and SL in SLN-positive patients: As described by [Thomas and Clark (2004)](#bib22){ref-type="other"}, patients having SLNB have approximately double the incidence of local/in-transit recurrence, while SLN-positive patients having SL have greater than four times the expected incidence.

In our series, 3-year disease-free and overall survival rates were 75.0 and 90.4%, respectively. Upon multivariate analysis, tumour thickness, ulceration and SLN status were all found to be significant factors with respect to disease-free survival. With respect to the overall survival upon multivariate analysis, tumour thickness was the only significant factor, and neither SLN status nor ulceration. This could be explained in part by the short follow-up period of our study. In contrast to this assumption, two other studies by Nowecki and Cascinelli with similar follow-up periods of 34 and 29 months, respectively, all showed a significant impact of SLN status on overall survival upon multivariate analysis ([Cascinelli *et al*, 2000](#bib5){ref-type="other"}; [Nowecki *et al*, 2003](#bib18){ref-type="other"}). Furthermore, Meier demonstrated that distant metastasis in patients with prior metastasis to lymph nodes already evolves after a median follow-up period of 25 months ([Meier *et al*, 2002](#bib14){ref-type="other"}).

An alternative explanation for this finding could be that the patient characteristics in our study group differ from other studies as 3-year overall survival for SLN-positive patients was substantially higher in our study if compared to [Gershenwald *et al* (1999)](#bib11){ref-type="other"} (83 *vs* 69.9%). This is not the case as the median tumour thickness of SLN-positive patients was identical in both studies (3.0 mm). Likewise, neither percentage of ulcerated tumours nor number of positive lymph nodes were substantially different from our study.

In conclusion, our study, including more than 300 patients, supports the influence of SLNB on disease-free survival, and is in accordance with previous studies in demonstrating the impact of tumour thickness, ulceration of the primary tumour and Clark level \>2 on the occurrence of positive SLNs. In contrast to previous studies, no statistically significant correlation between SLN status and overall survival was observed in our study population.

![Kaplan--Meier curves for overall (left panel) and disease-free (right panel) survival for patients undergoing successful SLNB. The 3-year disease-free survival was 82% and 55% for negative and positive SLN patients, respectively. The 3-year overall survival was 93 and 83% for negative and positive SLN patients, respectively.](92-6602391f1){#fig1}

###### 

Clinical and pathologic characteristics of the melanoma patient population (*n*=309)

                                                           **No.**   **%**
  -------------------------------------------------------- --------- -------
  *Sex*                                                              
   Female                                                  131       42
   Male                                                    178       58
                                                                     
  *Age*                                                              
   Mean                                                    55.8       
   Range                                                   18--86     
                                                                     
  *Site of primary tumour*                                           
   Head and neck                                           15        5
   Upper extremity                                         32        10
   Lower extremity                                         74        24
   Acral                                                   24        8
   Trunk                                                   164       53
                                                                     
  *Breslow thickness (mean: 2.7 mm; range: 0.25--30 mm)*             
   ⩽1 mm                                                   41        13
   1.01--2 mm                                              139       45
   2.01--4 mm                                              80        26
   \>4 mm                                                  43        14
   Regr./subungual                                         6         2
                                                                     
  *Clark level*                                                      
   II                                                      8         3
   III                                                     70        23
   IV                                                      208       67
   V                                                       17        5
   Regr./subungual                                         6         2
                                                                     
  *Ulceration*                                                       
   Absent                                                  241       78
   Present                                                 66        21
   Subungual                                               2         1
                                                                     
  *Histological subtype*                                             
   Superficial spreading                                   105       34
   Nodular                                                 124       40
   Acrolentiginous                                         18        6
   Lentigous malignant                                     11        4
   Desmoplastic                                            1         0.3
   Unclassified                                            50        16

###### 

Number of lymph node basins and number of SLNs at SLNB

                    **Total**   **%**
  ----------------- ----------- -------
  *No. of basins*               
   1                264         85
   2                30          10
   3                5           2
   0                10          3
                                
  *No. of SLN*                  
   0                10          3
   1                124         40
   2                76          25
   3                55          18
   4                25          8
   5                9           3
   6                9           3
                                
  Total             309         100

SLN=sentinel lymph node; SLNB=sentinel lymph node biopsy.

###### 

Patient characteristics stratified by SLN status and SL status

                             **All patients**   **SLN negative**   **SLN positive**   **SLN and SL positive**                  
  -------------------------- ------------------ ------------------ ------------------ ------------------------- ---- ---- ---- ----
  Total                      299                100                230                77                        69   23   14   20
  *Sex*                                                                                                                        
   Male                      171                57                 126                74                        45   26   10   22
   Female                    128                43                 104                81                        24   19   4    17
                                                                                                                               
  *Site of primary tumour*                                                                                                     
   Trunk                     158                53                 120                76                        38   24   7    18
                                                                                                                               
  *Clark level*                                                                                                                
   II                        8                  3                  8                  100                       0    0    0    0
   III                       71                 24                 59                 83                        12   17   1    8
   IV                        202                67                 151                75                        51   25   13   25
   V                         12                 4                  6                  50                        6    50   0    0
   Regr./subungual           6                  2                  6                  100                       0    0    0    0
                                                                                                                               
  *Ulceration*                                                                                                                 
   Absent                    226                76                 180                80                        46   20   9    20
   Present                   67                 22                 44                 66                        23   34   5    22
   Regr./subungual           6                  2                  6                  100                       0    0    0    0
                                                                                                                               
  *Tumour thickness (mm)*                                                                                                      
   ⩽1                        24                 8                  23                 96                        1    4    0    0
   1.01--2                   129                43                 109                84                        20   16   2    10
   2.01--4                   92                 31                 68                 74                        24   26   9    38
   \>4                       48                 16                 24                 50                        24   50   3    13
   Regr./subungual           6                  2                  6                  100                       0    0    0    0

SLN=sentinel lymph node; SL=selective lymphadenectomy.

###### 

Distribution of patients according to SL status and positive SLN status

             **SLN-positive patients (*n*=69)**              
  ---------- ------------------------------------ ----- ---- -----
  Negative   38                                   81%   15   73%
  Positive   7                                    15%   7    27%
  Not done   2                                    4%    0    0%

SLN=sentinel lymph node; SL=selective lymphadenectomy.

###### 

First site of recurrence and death of disease

                          **Locoregional skin**   **Draining LN basin**   **Systemic**   **Total recurrence**   **Death of disease**
  ---------------------- ----------------------- ----------------------- -------------- ---------------------- ----------------------
  SLN neg (*n*=230)             6 (2.6%)                7 (3.0%)            9 (3.9%)          22 (9.5%)               9 (3.9%)
  SLN pos (*n*=69)             12 (17.4%)               5 (7.2%)           8 (11.6%)          25 (36.2%)             9 (13.0%)
  SLN unknown (*n*=10)           0 (0%)                 1 (10.0%)          1 (10.0%)          2 (20.0%)              2 (20.0%)
                                                                                                               
  Total                         18 (5.8%)               13 (4.2%)          18 (5.8%)          49 (15.8%)             20 (6.5%)

SLN=sentinel lymph node; LN=lymph node.

###### 

Multivariate analysis of prognostic variables influencing disease-free and overall survival

                     **Disease-free survival**   **Overall survival**                                  
  ------------------ --------------------------- ---------------------- -------------- ------- ------- --------------
  Tumour thickness   \<0.001                     1.067                  1.010--1.127    0.002   1.098   1.036--1.165
  Ulceration         0.003                       2.230                  1.103--4.509                          
  SLN status         \<0.001                     4.264                  2.216--8.205                          

HR=hazard ratio; CI=confidence interval.

###### 

Report of recurrence rates in SLN-negative and -positive patients in the literature

  **Author**                                                                                   **SLN neg. (%)**   **SLN pos. (%)**   **Follow-up period (months)**
  -------------------------------------------------------------------------------------------- ------------------ ------------------ -------------------------------
  [Fincher *et al* (2003)](#bib9){ref-type="other"}                                            10                 26.3               50/38
  [Wagner *et al* (2003)](#bib25){ref-type="other"}                                            12.1               36.5               31.4
  [Chao *et al* (2002)](#bib7){ref-type="other"}                                               6.0                15.5               16
  [Gershenwald *et al* (1998)](#bib10){ref-type="other"}, [(1999)](#bib11){ref-type="other"}   11                 ---                35
  [Vuylsteke *et al* (2003)](#bib24){ref-type="other"}                                         14                 55                 72
  [Statius-Muller *et al* (2002)](#bib20){ref-type="other"}                                    11                 46                 38
  Current study                                                                                9.5                36.2               22

SLN=sentinel lymph node.
